106 related articles for article (PubMed ID: 15692156)
1. [Aldosterone and magnesium].
Matsuoka H
Clin Calcium; 2005 Feb; 15(2):187-91. PubMed ID: 15692156
[TBL] [Abstract][Full Text] [Related]
2. Potassium deficiency and cardiac function: experimental and clinical aspects.
Lüderitz B
Magnesium; 1984; 3(4-6):289-300. PubMed ID: 6536838
[TBL] [Abstract][Full Text] [Related]
3. [Effects of potassium on renin and aldosterone].
Kotchen TA
Arch Mal Coeur Vaiss; 1984 Apr; 77 Spec No():87-91. PubMed ID: 6428366
[TBL] [Abstract][Full Text] [Related]
4. Cardioprotection by aldosterone receptor antagonism in heart failure. Part I. The role of aldosterone in heart failure.
Dieterich HA; Wendt C; Saborowski F
Fiziol Cheloveka; 2005; 31(6):97-105. PubMed ID: 16366159
[TBL] [Abstract][Full Text] [Related]
5. The aldosterone antagonist and facultative diuretic eplerenone: a critical review.
Reyes AJ; Leary WP; Crippa G; Maranhão MF; Hernández-Hernández R
Eur J Intern Med; 2005 Feb; 16(1):3-11. PubMed ID: 15733814
[TBL] [Abstract][Full Text] [Related]
6. Spironolactone reduced arrhythmia and maintained magnesium homeostasis in patients with congestive heart failure.
Gao X; Peng L; Adhikari CM; Lin J; Zuo Z
J Card Fail; 2007 Apr; 13(3):170-7. PubMed ID: 17448413
[TBL] [Abstract][Full Text] [Related]
7. Potassium and magnesium depletions in congestive heart failure--pathophysiology, consequences and replenishment.
Iezhitsa IN
Clin Calcium; 2005 Nov; 15(11):123-33. PubMed ID: 16272623
[TBL] [Abstract][Full Text] [Related]
8. [Role of magnesium in cardiac metabolism].
Kurabayashi M
Clin Calcium; 2005 Nov; 15(11):77-83. PubMed ID: 16272616
[TBL] [Abstract][Full Text] [Related]
9. Diuretics and bone loss in rats with aldosteronism.
Law PH; Sun Y; Bhattacharya SK; Chhokar VS; Weber KT
J Am Coll Cardiol; 2005 Jul; 46(1):142-6. PubMed ID: 15992648
[TBL] [Abstract][Full Text] [Related]
10. Eplerenone: new drug. Recent myocardial infarction with heart failure: a spironolactone me too.
Prescrire Int; 2006 Apr; 15(82):46-9. PubMed ID: 16604728
[TBL] [Abstract][Full Text] [Related]
11. Role of aldosterone in angiotensin II-induced cardiac and aortic inflammation, fibrosis, and hypertrophy.
Neves MF; Amiri F; Virdis A; Diep QN; Schiffrin EL;
Can J Physiol Pharmacol; 2005 Nov; 83(11):999-1006. PubMed ID: 16391708
[TBL] [Abstract][Full Text] [Related]
12. Sodium retention in heart failure and cirrhosis: potential role of natriuretic doses of mineralocorticoid antagonist?
Bansal S; Lindenfeld J; Schrier RW
Circ Heart Fail; 2009 Jul; 2(4):370-6. PubMed ID: 19808361
[TBL] [Abstract][Full Text] [Related]
13. [Diuretic therapy in heart failure].
Splendiani G; Condò S
G Ital Nefrol; 2006; 23 Suppl 34():S74-6. PubMed ID: 16634001
[TBL] [Abstract][Full Text] [Related]
14. Aldosterone and cardiovascular disease.
Gaddam KK; Pimenta E; Husain S; Calhoun DA
Curr Probl Cardiol; 2009 Feb; 34(2):51-84. PubMed ID: 19135616
[TBL] [Abstract][Full Text] [Related]
15. The spironolactone, amiloride, losartan, and thiazide (SALT) double-blind crossover trial in patients with low-renin hypertension and elevated aldosterone-renin ratio.
Hood SJ; Taylor KP; Ashby MJ; Brown MJ
Circulation; 2007 Jul; 116(3):268-75. PubMed ID: 17606839
[TBL] [Abstract][Full Text] [Related]
16. Urocortin 2 inhibits furosemide-induced activation of renin and enhances renal function and diuretic responsiveness in experimental heart failure.
Rademaker MT; Charles CJ; Nicholls MG; Richards AM
Circ Heart Fail; 2009 Nov; 2(6):532-40. PubMed ID: 19919977
[TBL] [Abstract][Full Text] [Related]
17. Hyperparathyroidism and the calcium paradox of aldosteronism.
Chhokar VS; Sun Y; Bhattacharya SK; Ahokas RA; Myers LK; Xing Z; Smith RA; Gerling IC; Weber KT
Circulation; 2005 Feb; 111(7):871-8. PubMed ID: 15710759
[TBL] [Abstract][Full Text] [Related]
18. Aldosterone blockage in proliferative glomerulonephritis prevents not only fibrosis, but proliferation as well.
Gullulu M; Akdag I; Kahvecioglu S; Filiz G; Savci V
Ren Fail; 2006; 28(6):509-14. PubMed ID: 16928621
[TBL] [Abstract][Full Text] [Related]
19. [The AREA IN-CHF trial (antiremodeling effect of aldosterone receptors blockade with canrenone in mild chronic heart failure): rationale and design].
Cacciatore G; Boccanelli A; Mureddu GF; Maggioni AP; Latini R; Masson S; de Simone G;
Ital Heart J; 2005 May; 6 Suppl 1():66S-74S. PubMed ID: 15945301
[TBL] [Abstract][Full Text] [Related]
20. Spironolactone has antiarrhythmic activity in ischaemic cardiac patients without cardiac failure.
Shah NC; Pringle SD; Donnan PT; Struthers AD
J Hypertens; 2007 Nov; 25(11):2345-51. PubMed ID: 17921831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
